Fandomfare Gaming Pop up Health care News
In the first big merger of 2019, Bristol-Myers Squibb (NYSE
the pharma monster Bristol-Myers Squibb has gobbled up the biotech goliath Celgene in a $74 billion arrangement.
Celgene investors will get one BMS share and $50 money for each Celgene share they possess, esteeming the New Jersey-based Celgene at about $102.43 an offer, as per the organizations. That is about 54% more than Celgene’s end cost on Wednesday.
Latest posts by JADIRI GAMER (see all)
- SQUARE ENIX AND DISNEY DEBUT CLASSIC KINGDOM HEARTS ADVENTURES ON XBOX ONE - February 18, 2020
- FINAL FANTASY XIV ONLINE PATCH 5.2 – ECHOES OF A FALLEN STAR ARRIVES TODAY - February 18, 2020
- Nifty Games Teams Up With The NBA And NBPA To Bring Head-To-Head Basketball Action To Mobile Devices - February 18, 2020